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Abstract  
Background: The prevalence of diabetes mellitus as a non-communicable diseases increase 
annually. The global prevalence doubled from 4.7% to 8.5% in 1980 until 2016. Insulin resistance is 
the primary cause of type 2 diabetes mellitus. Polyunsaturated fatty acid has a contribution to 
membrane fluidity as well as the cell signaling system. The result of studies about the correlation 
between Omega-3 supplementation and blood glucose control in patients with type 2 diabetes is 
still inconsistent. Meanwhile, we considered to give a 86 year old woman with an uncontrolled type 
2 diabetes omega-3 fatty acid supplementation for controlling her blood glucose. Thus, we 
performed an evidence-based case report to respond this problem. 
Objectives: To observe the effect of omega-3 supplementation on glycated hemoglobin (HbA1c) 
serum of type 2 diabetes mellitus patients.   
Methods: Electronic literature searching was performed with Cochrane®, Scopus®, and Pubmed®. 
Inclusion and exclusion criteria were applied by MeSH term and title/abstract with clinical trial as 
the study design. Critical appraisal was performed for eligible article. 
Results: There were three articles relevant with the eligibility criteria and clinical question. One 
study  found that omega-3 supplementation did not give a significant effect on HbA1c. The other 
two studies. found that there were improvement on HbA1c and lipid profile in patients that 
consumed omega 3.  
Conclusions: Omega-3 supplementation has inconsistent results for the improvement of HbA1c. 
The omega-3 lowering effect of HbA1c depends on the source, dosage, and duration of 
supplementation. 
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Clinical scenario 
 
An 86-year-old woman was admitted to the hospital 
with a chief complaint of decreased of  
 
appetite for three days before admission. She also 
complained cough and nausea with the absence of 
fever or vomiting. Her blood glucose level on the 
first day of care was 161 mg/dl. She was diagnosed 
with diabetes mellitus since two years ago and 
hypertension since seven years ago. She also has 
decreased kidney function since two years ago. She 
stopped taking oral hypoglycemic drugs since one 
year ago because of her daily blood glucose was 
within normal limits. Her blood glucose kept on 
increasing during the hospitalization that caused her 
to take oral hypoglycemic drugs to overcome her 
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high blood glucose level. Her blood glucose on the 
second and third admission day reached 241 mg/dL 
despite her regular oral hypoglycemic drugs intake. 
The physical examination revealed that this 
patient has an irregular heart beat. She was given 
enteral nutrition by nasogastric tube since the first 
day of admission. Her nutritional status was mild 
malnutrition with the body mass index of 18 
kg/m2. Clinical nutrition specialist planned to give 
her omega-3 supplementation to decrease HbA1c 
but whether omega-3 supplementation will give a 
significant effect on this patient was still on 
consideration. 
Introduction 
 
Diabetes is a chronic disease caused by the inability 
of the pancreas to produce insulin or insulin-
resistant, manifested as high blood glucose level or 
hyperglycemia.2,3  The prevalence of diabetes 
mellitus as one of non-communicable disease tend 
to increase annually.3 The global prevalence of 
diabetes doubled since 1980 from 4,7% to 8,5% in 
2016.2 Diabetes prevalence in Indonesia is increased 
1.7% from 2013 until 2018. 4   
Diabetes mellitus can be classified as type one 
and type two diabetes mellitus. Type two diabetes is 
more prevalent than type one diabetes mellitus.2 
Type two diabetes mellitus is caused by insulin-
resistance that occur in the muscle and liver.3 High-
fat diet, especially saturated fat, will reduced insulin 
sensitivity that lead to insulin resistance.5 On the 
other side, high polyunsaturated fat intake will 
improve insulin secretion and sensitivity. 
Physiologically, polyunsaturated fatty acid 
maintains the cell membrane fluidity to facilitate cell 
signaling pathway that augment insulin sensitivity. 6  
There are many literatures that report the 
correlation between omega-3 fatty acid 
supplementation and insulin resistance, but only a 
few that use HbA1c as a parameter of the study. It is 
still under debate, whether omega-3 
supplementation increase insulin sensitivity in 
patients with type two diabetes mellitus. Various 
dosage regimen is one of the reason for this 
inconsistent result other than difference in length of 
supplementation.7 Whether omega-3 
supplementation has a positive effect on blood 
glucose management, observed with the HbA1c 
level in geriatric population as our patient suffered 
from, is an interesting field to study. 
 
Clinical questions 
 
The inclusion criteria for the subjects in this study 
are geriatric patients diagnosed with diabetes 
mellitus type 2. Glycate hemoglobin is the outcome 
of this study that compose the clinical question. 
The clinical question of this study: Can omega-3 
supplementation reduce HbA1c levels in patients 
with diabetes mellitus type 2?  
 
P       : geriatric patients that is diagnosed to have 
diabetes mellitus type 2 
I        : omega-3 supplementation 
C     : placebo 
O      : HbA1c 
 
Methods 
 
Search Strategy 
Advanced searching was used for this literature 
searching from three main databases: Pubmed®, 
Cochrane®, and Scopus® on December 19th, 2019. 
MesH Term and abstract/title was used as the 
searching criteria with the keywords of “omega 3 
fatty acid”, “alpha-linolenic acid”, “HbA1c”, “A1c”, 
dan “diabetes mellitus”. The result of this literature 
searching was then screened with EndNote™ 
application to eliminate duplication. Full text 
literatures which met the eligibility criteria and 
PICO were critically appraised. 
 
Strategy of article selection 
 
Eligibility Criteria 
 
The articles were selected based on the inclusion and 
exclusion criteria, which is in line with the clinical 
question.  The inclusion criteria were: 1) participants 
diagnosed as type 2 diabetes mellitus; 2) Geriatric 
patients (aged ≥60 years old); 3) Same 
characteristics subjects; 4) HbA1c measurement was 
done before and after intervention; 5) Randomized 
clinical trial 6) HbA1c as the study outcome and 7) 
publication within the last 5 years. The exclusion 
criteria were: 1) no available full text and 2) 
language other than English. 
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Critical appraisal 
Critical appraisal was based on a therapy study, with 
HbA1c as the outcome measured. All of the relevant 
articles were assessed for validity, importance, 
applicability (VIA) with standardized critical 
appraisal for therapy study. 
 
Results 
 
A total of 793 articles were identified from 
Pubmed®, 13 from Cochrane®, and 43 from Scopus® 
based on keywords, MesH Terms, abstract/title 
(Table 1).  
That literature was screened for titles that 
contain keywords listed. The result of the title 
screened was 15 relevant literatures that is eligible 
for the next screening step. All these relevant 
literature was screened for inclusion and exclusion 
criteria, 3 literatures fulfilled the eligibility criteria. 
Among 12 literatures that excluded, 10 literatures 
used outcome measure other than HbA1c and 2 
literatures included Participants below 60 years of 
age. (Figure 1). 
All of these three literatures used randomized 
double-blind controlled trials as their study design 
with a level of evidence of 2.The participants were 
diagnosed with diabetes and received omega-3 fatty 
acid. The HbA1c examination was performed to all 
the participants as one of their clinical outcomes. 
Study characteristics are shown in table 2. Zeng et 
al. almost fulfill all the appraisal criteria, followed 
by Wang et al. that did not fulfill two criteria, and 
Soleimani et al that did not fulfill three appraisal 
criteria.  
 
Discussion 
 
Soleimani et al.10 conducted a randomized double-
blind placebo-controlled clinical trial to 60 
participants with diabetic foot ulcer grade 3 by 
Wagner-Meggit’s criteria. Participants included in 
this study ranged from 40 years old until 85 years 
old. Participants were divided into two groups with 
one group was given omega-3 fatty acid from 
flaxseed oil 1 g/day for 12 weeks and the other one 
was given placebo both for 12 weeks. Participants 
were monitored during the 3rd week, 6th week, 9th 
week, and 12th week. The primary outcome of this 
study was wound healing and glucose homeostasis, 
the secondary outcome was lipid profile, 
inflammatory biomarker, and oxidative stress. The 
result of this study was the improvement of wound 
healing and reduction of insulin serum, HOMA-IR, 
and HbA1c, also an increase in QUICKI. The 
secondary outcome was reduction in hs-CRP but 
there is no significant difference in lipid profile 
between intervention and placebo group.  Omega-3 
from flaxseed oil 2 grams/day can reduce of HbA1c 
from baseline 7.5 +/- 1.5% compare to the end-of-
trial 6.6 +/- 1.4% that change about -0.9 +/- 1.5%, 
(p=0.01).10  
Wang F et al.1 conducted a randomized, double-
blind, placebo-controlled trial, to 100 participants 
age 65,4 +/- 5,3 years old diagnosed as type 2 
diabetes mellitus and central obesity. Participants 
were divided into an intervention group that was 
given omega-3 from fish oil 4 grams/day that 
contains 1.34 g EPA and 1.07 g DHA compared with 
placebo for 6 months. Participants were monitored 
for their conformity monthly by returning the empty 
bottle that was filled by the omega-3 capsule before. 
The result of this study is that omega-3 fatty acid 
from fish oil was not significantly different 
compared with placebo in terms of HbA1 reduction 
with baseline 7.72 +/- 1.23%, 3rd month 7.85 +/- 
1.55%, and 6th month 7.34 +/- 1.51%  (p=0.901). 
There is a significant reduction in triglyceride 
(p=0,007) and increase in HDL (p=0,006) when 
compared to placebo in this study.1  
A double-blind randomized controlled trial was 
conducted by Zheng J.S et al.11 to 185 participants 
that were diagnosed with type 2 diabetes mellitus 
aged 35 until 80 years old. The participants were 
divided into three intervention groups that were fish 
oil group, flaxseed oil group, and corn oil group. All 
the participants were given capsules containing EPA 
and DHA 4 times a day for 180 days. Participants in 
the fish oil group were given 2 grams of omega-3 
fatty acid containing EPA and DHA, meanwhile, 
participants in the flaxseed oil group received 2.5 
grams of alpha-linolenic acid. Participants were 
monitored on the 90th day and 180th day by returning 
their omega-3 bottle. Trained nurses make a phone 
call once a month to make sure every participant 
consumed the omega-3 capsule that was given. The 
result of this study is that omega-3 fatty acid from 
fish oil reduced HbA1c better than flaxseed and corn 
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oil group (p=0,037). Triglyceride, low-density 
lipoprotein, and total cholesterol decreased more 
significantly in the fish oil group than the other 
groups (p<0.05). Flaxseed oil group and the corn oil 
group did not differ significantly.11  
The HbA1c lowering effect of omega-3 fatty 
acid from study of Soleimani et al.10 can be 
explained due to the effect of omega-3 fatty acid on 
modulating peroxisome proliferator-activated 
receptors and increasing gene expression of G 
protein-coupled receptor 120 that related to insulin 
metabolism.10 Wang F et al.1 found that there is no 
significant effect of omega-3 supplementation on 
HbA1c.1 Difference between study results might be 
related to differences in sample size, source of 
omega-3 fatty acids, dosage of daily omega-3 
supplementation, duration of supplementation, or 
participant disease characteristic.  
Zheng J.S et al.11 found that there are different 
effectivity of omega-3 fatty acids from different 
sources of omega-3 fatty acids such as fish oil, 
flaxseed oil, and corn oil. The result of this study 
explained that fish oil reduced HbA1c better than 
flaxseed oil and corn oil. Fish oil given in this study 
was 2 grams for 6 months.11 Fish oil contain 
eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) as compared to alpha-linolenic acid of 
flaxseed oil that need to be converted to EPA and 
DHA.12  
In our case of geriatric 86 years old woman 
suffered from type 2 diabetes mellitus with 
increasing blood glucose during hospitalization. Her 
age and diagnosis are similar to these studies. We 
recommended on giving omega-3 fatty acids from 2 
grams of fish oil daily besides continuous medical 
nutritional therapy to improve the patient's HbA1c.   
 
Conclusions 
 
The effect of omega-3 fatty acid to decrease HbA1c 
still has no consistent result. This can be explained 
by the difference in the dosage and duration of 
supplementation. Although there were still 
inconsistent results, 2 out of 3 literatures in this 
study conclude that omega-3 fatty acids give a 
significant effect on the reduction of HbA1c. 
Omega-3 fatty acids from fish oil give better effect 
when compared to omega-3 from flaxseed oil and 
corn oil for HbA1c and lipid profile improvement. 
The effect of omega-3 fatty acid for HbA1c 
reduction depends on the source, dosage, and 
duration of supplementation. The limitation of this 
study are no precise dosage and explanation whether 
age will affect the result of the study, there is no 
study that explain whether different age population 
will give different response to omega-3 
supplementation. Further research is needed to 
confirm the effect of omega-3 supplementation on 
HbA1c.    
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Table 1. Resources & search strategy 
Database Search  Strategy Hits Choosen 
Pubmed (((((((((omega 3 fatty acids[MeSH Terms]) OR omega 3 fatty 
acids[Title/Abstract]) OR alpha linolenic acid[MeSH Terms]) OR alpha 
linolenic acid[Title/Abstract]) AND hb a1c[MeSH Terms]) OR hb 
a1c[Title/Abstract]) OR A1c[MeSH Terms]) OR A1c[Title/Abstract]) AND 
diabetes mellitus[MeSH Subheading]) OR diabetes mellitus[Title/Abstract] 
793 4 
Cochrane 
Library 
ID Search Hits 
#1("omega 3 fatty acids"):ti,ab,kw 2010 
#2 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees 2923 
#3("alpha-linolenic acid"):ti,ab,kw 0 
#4MeSH descriptor: [alpha-Linolenic Acid] explode all trees 226 
#5("Hb A1C values"):ti,ab,kw 374 
#6 MeSH descriptor: [Glycated Hemoglobin A] explode all trees 5458 
#7("glycated haemoglobin levels"):ti,ab,kw 191 
#8 MeSH descriptor: [Glycated Hemoglobin A] explode all trees 5458 
#9("diabetes mellitus"):ti,ab,kw 59410 
#10 MeSH descriptor: [Diabetes Mellitus] explode all trees 28035 
#11#1 OR #2 OR #3 OR #4 4317 
#12#5 OR #6 OR #7 OR #8 5851 
#13#9 OR #10 62938 
#14#11 AND #12 AND #13 with Cochrane Library publication date Between 
Jan 2017 and Dec 2019, in Trials 13 
13 6 
Scopus ( TITLE-ABS-KEY ( omega  3  fatty AND acids )  OR  TITLE-ABS 
KEY ( alpha AND linolenic AND acid )  AND  TITLE-ABS-
KEY ( hb AND a1c )  OR  TITLE-ABS-KEY ( a1c )  AND  TITLE-ABS-
KEY ( diabetes  AND mellitus ) )  AND  DOCTYPE ( ar )  AND  PUBYEAR 
 >  2016  AND  ( LIMIT-TO ( DOCTYPE ,  "ar" ) )  AND  ( LIMIT-
TO ( SUBJAREA ,  "MEDI" ) )  AND  ( LIMIT-
TO ( EXACTKEYWORD ,  "Human" ) )  AND  ( LIMIT-
TO ( LANGUAGE ,  "English" ) )  AND  ( LIMIT-TO ( SRCTYPE ,  "j" ) )  
 
43 5 
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Table 2. Study characteristics 
Articles Study design Intervention Population Outcome 
Soleimani Z et 
al. (2017) 
A 
randomized, 
double-blind, 
placebo-
controlled 
trial 
Flaxseed oil 1 
grams/day for 
12 week 
compared 
with placebo 
60 patients, 45-80 years old 
diagnosed with grade 3 diabetic 
foot ulcer grade 3 (Wagner-
Meggitt's criteria) with cellulitis 
and normal distal pulse. 
Wound healing, glucose 
homeostasis parameter (serum 
insulin concentration, homeostasis 
model of assessment-insulin 
resistance (HOMA-IR), 
quantitative insulin sensitivity 
check index (QUICKI), 
Hemoglobin A1c (HbA1c), and 
fasting plasma glucose), and lipid 
profiles. 
Wang F et al., 
(2017) 
A 
randomized, 
double-blind, 
placebo-
controlled 
trial 
Fish oil 4 
grams/day 
compared 
with placebo 
for 6 month 
100 Participants, >60 years old 
diagnosed with type 2 diabetes 
by World Health Organization 
(WHO) criteria and abdominal 
obesity by Working Group on 
Obesity of China (WGOC) 
criteria. 
Waistline, hipline, height, systolic 
and diastolic blood pressure, serum 
fatty acid composition and body 
composition, body composition, 
serum glucose, HbA1c, insulin, 
triglyceride (TG), total cholesterol 
(TC), high-density lipoprotein 
cholesterol (HDL-C), and low-
density lipoprotein cholesterol 
(LDL-C). 
Zeng J.S et al., 
(2016) 
Double-blind 
randomized 
controlled 
trial 
Fish oil 2 
grams/day, 
flaxseed oil 
2.5 
grams/day. 
185 Participants, 35-80 years old 
for men and between post-
menopausal age until 80 years 
old for woman. Fasting blood 
glucose >7.0 mmol/L or use of 
diabetic medications. 
Fasting blood glucose, HDL-C, 
LDL-C, total cholesterol, TG, 
glucose, uric acid, blood urea 
nitrogen (BUN), creatinine, liver 
function markers, blood total 
protein, globulin (GLB), albumin 
(ALB), total bilirubin (TBIL), 
direct bilirubin (DBIL), indirect 
bilirubin (IDBIL), HOMA-IR, 
HbA1c 
ALB: albumin, BUN: blood urea nitrogen, DBIL: direct bilirubin, IDBIL: indirect bilirubin, GLB: globulin, HbA1c: 
hemoglobin A1c, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein, HOMA-IR: homeostasis 
model of assessment-insulin resistance, TBIL: total bilirubin, TC: total Cholesterol TG: triglyceride, QUICKI: quantitative 
insulin sensitivity check index,   
 
Table 3. Validity criteria 
Validity Relevance   
Articles 
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C
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Result Level of 
Evidence9 
Soleimani et al10 +  + + + +   - - A 2 
Wang Fet al1 + + + - +  + - B 2 
Zheng, J.S et al11 + + + ? +  + + C 2 
A: Significant reduction of HbA1c in the intervention group (p=0.01)10 
B: Reduction of HbA1c did not differ significantly between the intervention group and placebo group (p>0.05).1 
C: HbA1c significantly decreased statistically in the fish oil group compared with the flaxseed oil and corn oil group 
(p<0,001).11 
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Table 4. Relevance criteria 
 Similarity Population Similarity Determinant Similarity Outcome 
Soleimani et al10 + + + 
Wang F et al1 - + + 
Zheng J.S et al11 + + + 
 
 
Table 5. Result of studies 
Articles Outcome Key Results 
Soleimani Z, 
Hashemdokht F, 
Bahmani F, Taghizadeh 
M, Memarzadeh MR, 
Asemi Z. (2017) 
Journal of Diabetes 
and Its Complications10 
• Wound healing 
• Serum insulin, homeostasis model of assessment-
estimated insulin resistance (HOMA-IR), 
quantitative insulin sensitivity check index 
(QUICKI), HbA1c. 
• Lipid profile: triglyceride, VLDL, LDL, HDL 
• Inflammation marker: high sensitivity C-reactive 
protein (hs-CRP), nitric oxide, total antioxidant 
capacity (TAC), glutathione total (GSH), dan 
malondialdehyde (MDA) 
• The reduction in wound size is more 
significant in 12 weeks omega-3 
supplemented participants  
• The reduction of insulin concentration, 
HOMA-IR, and HbA1c is statistically 
significant. 
• The result for HbA1c: baseline 7.5 +/- 
1.5%, end-of-trial 6.6 +/- 1.4%, change -
0.9 +/- 1.5%, p=0.01  
• The increase in QUICKI is also 
statistically significant 
Wang F, Wang Y, Zhu 
Y, et al. (2016), 
European Journal of 
Nutrition10 
• Fasting blood glucose, HbA1c, insulin, HOMA- 
• Lipid profile such as triglyceride, LDL, HDL 
• Omega-3 supplementation for 12 weeks 
reduced triglyceride level significantly 
(P=0,007) 
• Omega-3 supplementation were not 
statistically significant  in affecting 
HOMA-IR, fasting blood glucose, and 
HbA1c  
• The result for HbA1c baseline was 7.72 
+/- 1.23%, 3 months 7.85 +/- 1.55%, 6 
months 7.34 +/- 1.51%, p=0.901 
 
Zheng JS, Lin M, Fang 
L,(2016), Molecular 
Nutrition & Food 
Research Journal11 
• Fasting blood glucose, fasting plasma insulin, 
HOMA-IR, HbA1c. 
• HDL, LDL, triglyceride, and total cholesterol 
• BUN, creatinine, uric acid, ALT, AST, total 
bilirubin, direct bilirubin, indirect bilirubin, total 
protein, globulin, and albumin. 
• Omega-3 fatty acid from fish oil gives a 
better statistically significant effects on 
glycemic control and lipid profile 
compared with flaxseed oil and corn oil. 
• HbA1c reduction is statistically 
significant in fish oil group compared 
with flaxseed and corn oil. (on day 0: 
63.9 +/- 22.9 mmol/mol, on day 90th: 
52.7 +/- 13.8 mmol/mol, on day 180th: 
54.4 +/- 13.4 mmol/mol,  p=0.035) 
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Figure 1. Prima’s flow chart of literature searching 
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